We claim:

1. ~~A~~Use of an effective dose of masupirdine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament ~~method~~ for the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia~~,comprising administering to the patient an effective dose of masupirdine or a pharmaceutically acceptable salt thereof~~, wherein the effective dose of masupirdine or a pharmaceutically acceptable salt thereof is selected from 25 mg to 125 mg, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia.

2. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 25 mg to 50 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient.

3. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 50 mg to 100 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient.

4. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 25 mg, 50 mg, 75 mg, 100 mg or 125 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient.

5. The ~~method~~ use of any one of claims 1 to 4, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

6. The use~~method for the treatment~~ as claimed in claim 5~~1~~, wherein ~~comprising administering to~~ the patient is to be administered an effective dose of

masupirdine dimesylate monohydrate, wherein the effective dose of masupirdine dimesylate monohydrate is selected from 25 mg to 125 mg.

7. The ~~method~~ use of claim 6, wherein ~~the treatment comprises administering to the patient~~ 25 mg, 50 mg, 75 mg, 100 mg or 125 mg of masupirdine dimesylate monohydrate is to be administered to the patient.

8. The ~~method~~ use as claimed in any one of claims 1 to 4, wherein the ~~treatment comprises administering to the patient an~~ effective dose of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.

9. ~~A method for the treatment of agitation/aggression in a patient with Alzheimer's disease dementia comprising administering~~ Use of ~~an~~ the effective dose of masupirdine or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 in the manufacture of a medicament for the treatment of agitation/aggression in a patient with Alzheimer's disease dementia.

10. ~~A method for the treatment of delusions, hallucinations, or delusions and hallucinations in a patient with Alzheimer's disease dementia comprising administering~~Use of ~~an~~ the effective dose of masupirdine or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 in the manufacture of a medicament for the treatment of delusions, hallucinations, or delusions and hallucinations in a patient with Alzheimer's disease dementia.

~~11. A pharmaceutical composition, comprising an effective dose of masupirdine or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5, for use in the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia, wherein the dementia is selected from~~

~~Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia.~~

~~12. The pharmaceutical composition, consisting of an effective dose of masupirdine or a pharmaceutically acceptable salt thereof as claimed in claim 11, for use in combination with donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof, for the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia.~~

~~13. The pharmaceutical composition for use of claim 11 or 12, wherein the agitation/aggression is in a patient with Alzheimer's disease dementia.~~

~~14. The pharmaceutical composition for use of claim 11 or 12, wherein the delusions, hallucinations, or delusions and hallucinations are in a patient with Alzheimer's disease dementia.~~

~~15~~11. The ~~pharmaceutical composition for~~ use of claim ~~8~~11 ~~or 12~~, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

~~16~~12. The ~~method~~ use of claim 8 ~~or the pharmaceutical composition for use of claim 12~~, wherein the pharmaceutically acceptable salt of donepezil is hydrochloride.

~~17~~13. The ~~method~~ use of claim 8 ~~or the pharmaceutical composition for use of claim 12~~, wherein the pharmaceutically acceptable salt of memantine is hydrochloride.